Novartis submits application to FDA for Kymriah (tisagenlecleucel)
Novartis announced that the company has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for Kymriah™ (tisagenlecleucel)…
Read More...
Read More...
